Corporate Responsibility News
May 20, 2013
From Research Labs to Doctors' Offices, Health Care Providers at Lilly Play Important Role in Bringing New and Innovative Medicines to Patients
INDIANAPOLIS, May 20, 2013 /PRNewswire/ -- The many health care providers working at Eli Lilly and Company (NYSE:LLY) − including doctors, nurses, and pharmacists − play a vital role in bringing new and innovative medicines to patients. From research labs to doctors' offices, these Lilly employees bring unique insights about patients, a...
May 14, 2013
Lilly Oncology to Release New Pipeline Data at ASCO 2013
INDIANAPOLIS, May 14, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from key molecules that make up its clinical oncology pipeline during the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from May 31 — June 4, 2013. Lilly Oncology's pipeline is one of the most robust i...
May 14, 2013
Lilly Provides Update on CEO Dr. John Lechleiter
INDIANAPOLIS, May 14, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, underwent scheduled surgery for a dilated aorta on Monday, May 13, 2013.
"Dr. Lechleiter's surgeons have advised us that surgery went as expected and the repair to the a...
May 10, 2013
Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
INDIANAPOLIS, May 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL). The study failed to show a statistically significant increas...
May 6, 2013
Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Clinical Congress
RIDGEFIELD, Conn. and INDIANAPOLIS, May 6, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from two new pooled analyses of phase III data with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, presented at the American Association of Clinical Endocrinologists (AAC...
May 6, 2013
Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
INDIANAPOLIS, May 6, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, will undergo scheduled surgery for a dilated aorta on Monday, May 13, 2013. This condition was found during unrelated testing and has been asymptomatic. Lechleiter is expected t...
May 6, 2013
Lilly Declares Second-Quarter 2013 Dividend
INDIANAPOLIS, May 6, 2013 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the second quarter of 2013 of $0.49 per share on outstanding common stock.
The dividend is payable June 10, 2013 to shareholders of record at the close of business on May 16, 2013.
Lilly, a leading innov...
May 2, 2013
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
RIDGEFIELD, Conn. and INDIANAPOLIS, May 2, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the launch of an educational campaign designed to provide healthcare professionals (HCPs) with a greater understanding of the role sodium glucose co-transporters (SGLTs) play in maintaining...
May 1, 2013
The Importance of Emergency Preparedness: Lilly Diabetes and the American College of Endocrinology (ACE) Help Prep People with Diabetes for Emergencies - Big or Small
PHOENIX, May 1, 2013 /PRNewswire/ --
News Highlights:
ACE, Lilly Diabetes offer emergency tips for people w/ #diabetes at www.EmPowerYourHealth.org, tips now downloadable in Spanish
Lilly Diabetes and ACE have distributed approximately 12 million #diabetes emergency prep checklists since '06 www.EmPowerYourHealth.org
A hur...
April 30, 2013
Lilly Diabetes and Disney Publishing Worldwide Expand Collaboration
INDIANAPOLIS, April 30, 2013 /PRNewswire/ --
News Highlights:
Lilly Diabetes expands collaboration with Disney Publishing Worldwide globally.
New educational resources will be available soon for families of children with type 1 diabetes.
Lilly Diabetes today announced the global expansion of its innovative collaboration wit...
April 26, 2013
Lilly Celebrates National Volunteer Week with Deployment of Global Service Teams
INDIANAPOLIS, April 26, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) celebrated National Volunteer Week April 21-27 by sending off the first of 200 volunteers who will serve in impoverished communities throughout 2013. They are part of Connecting Hearts Abroad, Lilly's global employee volunteer program launched in 2011. Volunteer teams de...
April 24, 2013
Lilly Again Named One of DiversityInc's Top 50 Companies for Diversity
INDIANAPOLIS, April 24, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has been named to the DiversityInc "Top 50 Companies for Diversity" list for the third consecutive year.
DiversityInc's "Top 50 Companies for Diversity" is known as a leading assessment of diversity management globally. To make the list, participating companies m...
April 24, 2013
Lilly Reports First-Quarter 2013 Results
INDIANAPOLIS, April 24, 2013 /PRNewswire/ --
Worldwide revenue was flat as growth in key products offset lower Zyprexa revenue following patent expirations.
Cymbalta revenue increased 19 percent while Cialis increased 11 percent.
Expense controls resulted in lower SG&A, offsetting growth in R&D expense.
First quarter 2013 ...
April 17, 2013
Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimer's Disease Research and Development
INDIANAPOLIS, April 17, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it has acquired two investigational positron emission tomography (PET) tracers from Siemens Medical Solutions USA, Inc. The tracers are intended to image tau (or neurofibrillary) tangles in the brain, one of two known hallmarks of Alzheimer's disease. Bas...
April 16, 2013
Lilly Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes
INDIANAPOLIS, April 16, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.
Primary efficacy en...
April 10, 2013
Lilly Debuts Early Oncology Pipeline Data At AACR Annual Meeting
WASHINGTON, April 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) unveiled data from four key molecules that represent the next generation of its oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting held in Washington, D.C. from April 6-10. The data reflect Lilly's diverse oncology pipeline via molecule...
April 3, 2013
Lilly Confirms Date and Conference Call for First-Quarter 2013 Financial Results Announcement
INDIANAPOLIS, April 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2013 on Wednesday, April 24, 2013. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
The conference cal...
April 2, 2013
Potential Lilly Investment Would Further Expand Indianapolis Insulin Manufacturing Operations
INDIANAPOLIS, April 2, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it is working closely with the city on a proposal to invest an additional $180 million in the company's Indianapolis-based insulin manufacturing operations. The investment is in addition to the company's November 2012 announcement of a $140 million ex...
March 26, 2013
European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Company's empagliflozin*, an investigational type 2 diabetes treatment
RIDGEFIELD, Conn. and INDIANAPOLIS, March 26, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin*, for the treatm...
March 25, 2013
Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
RIDGEFIELD, Conn. and INDIANAPOLIS, March 25, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin* was recently submitted to the Food and Drug Administration (FDA) in the United States...
|
